NEW YORK, July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Companies, Inc. (NYSE: RKT). Shareholders who purchased shares of RKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: DEADLINE: July 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: htt ...

NEW YORK, July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Reddit, Inc. (NYSE: RDDT). Shareholders who purchased shares of RDDT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: DEADLINE: August 18, 2025 Shareholders should not delay in registering for this class action. Register your information here: https:// ...

Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - Wealth Minerals Ltd. (TSXV: WML) (OTCQB: WMLLF) (SSE: WMLCL) (FSE: EJZN) (the "Company" or "Wealth") announces that it has entered into a Memorandum of Understanding (the "MOU") with Voith Hydro Holding GmbH & Co KG ("Voith Hydro") to develop the Pabellón Lithium Project (see press releases of February 6, 2025 and March 18, 2025) jointly with the Quechua Indigenous Community of Ollagüe ("CIQO") and further partners.Under the terms of this MOU, ...

Vaisala CorporationPress releaseJuly 7, 2025, at 1:00 p.m. (EEST) Vaisala's Half Year Financial Report January–June 2025 to be published on July 25, 2025 Vaisala Corporation will publish its Half Year Financial Report January–June 2025 on Friday, July 25, 2025, at about 9:00 a.m. (Finnish time). The report will be available at vaisala.com/investors. The President and CEO's presentation will be published by 1:00 p.m. on the same day at vaisala.com/investors. Audiocast and teleconference An audiocast and a co ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from March 7, 2024, to March 3, 2025, and the lead plaintiff deadline is August 8, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [2][5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]. Group 3: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. - It is claimed that these misrepresentations led to an overstatement of the clinical, regulatory, and commercial prospects of PGN-ED051, ultimately resulting in investor damages when the truth was revealed [4].

RT Ahmed (@AraBalaghi)Appchain thesis in full swingThe amount of composability and app-straction that will need to exist for all L2s is going to 10x from here ...

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns related to its products [1][2]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [2]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [2]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process for Investors - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of federal securities law violations related to the safety of its product ELEVIDYS, which has been linked to patient deaths and adverse events [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Sarepta, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][12]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Safety Concerns and Stock Price Impact - The complaint alleges that Sarepta and its executives made false or misleading statements regarding the safety of ELEVIDYS, failing to disclose significant safety risks and adverse events [5]. - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [6]. - On April 4, 2025, after disclosing regulatory scrutiny and halting recruitment in clinical studies, the stock price dropped by $4.18 per share, or 7.13%, to close at $54.43 [8]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24 per share, or 42.12%, closing at $20.91 [10]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into acute liver failure risks associated with ELEVIDYS, resulting in a further stock price drop of $1.52 per share, or 8.01%, to close at $17.46 [10][11].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to allegations of false and misleading statements regarding the company's growth potential and operational capabilities [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who suffered losses exceeding $100,000 in Iovance between August 8, 2024, and May 8, 2025, are encouraged to contact the law firm for discussions on their legal rights [1][3]. Group 2: Financial Performance and Stock Impact - On July 25, 2024, Iovance announced its second-quarter financial results for fiscal 2024 and reduced its revenue guidance for the full year, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation [6]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [6]. Group 3: Allegations Against Iovance - The complaint against Iovance alleges that the company and its executives violated federal securities laws by failing to disclose the true state of the company's growth potential and operational readiness to meet demand for its treatments [5].

Core Viewpoint - 3D Systems Corporation is facing a federal securities class action lawsuit due to allegations of misleading statements regarding its financial performance and business conditions, with a deadline for investors to seek lead plaintiff status by August 12, 2025 [3][5]. Financial Performance - For Q4 2024, 3D Systems reported a non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, and sales revenue of $111 million, reflecting a year-over-year decline of 3.4% [6]. - The full-year 2024 sales totaled $440.1 million, a decrease of 10% compared to the previous year, attributed to lower hardware systems sales due to macroeconomic factors [6]. - In Q1 2025, the company reported revenue of $94.5 million, down 8% year-over-year, and a net loss of $37 million, or $0.28 per share, which more than doubled the loss from Q1 2024 [8]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [7]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, closing at $1.87 per share [9]. Legal Allegations - The lawsuit claims that 3D Systems and its executives violated federal securities laws by making false statements about the impact of weakened customer spending and overstating the company's resilience [5]. - The complaint also highlights that updated milestone criteria in the United Partnership would negatively affect the revenue from the Regenerative Medicine Program [5].